Estrone vs. Estradiol: Key Differences and Clinical Use in Hormone Replacement Therapy
Estradiol is the most potent endogenous estrogen and the preferred agent for hormone replacement therapy, while estrone is a weaker metabolite that becomes the predominant circulating estrogen after menopause but has distinct and potentially less favorable biological effects. 1
Fundamental Biological Differences
Estradiol (E2) is the principal intracellular human estrogen and is substantially more potent than estrone at the receptor level 1. In premenopausal women, the ovarian follicle secretes 70-500 mcg of estradiol daily depending on menstrual cycle phase. After menopause, most endogenous estrogen production shifts to estrone (E1), which is produced by peripheral tissue conversion of adrenal androgens 1.
The two estrogens exhibit fundamentally different biological activities:
- Estradiol promotes endothelial cell proliferation, migration, and tube formation in a dose-dependent manner 2
- Estrone produces biphasic effects on proliferation and tube formation, with minimal impact on cell migration 2
- When both estrogens are present together, high estrone-to-estradiol ratios actually decrease proliferative capacity, revealing a co-inhibitory relationship not previously recognized 2
- Estrone is pro-inflammatory and induces epithelial-to-mesenchymal transition (EMT) and cancer stem cell enrichment, while estradiol does not 3
Route of Administration Critically Affects Estrone/Estradiol Ratios
The route of estradiol administration dramatically impacts the resulting estrone-to-estradiol ratio, which has significant clinical implications:
- Oral estradiol: Produces E1/E2 ratio of ~9.28, with 5-fold higher estrone levels and 10-20 fold higher estrone sulfate than transdermal routes 4, 5
- Sublingual estradiol: E1/E2 ratio of ~6.88 5
- Transdermal estradiol (patches, gels, sprays): E1/E2 ratio of ~2.22 5
- Injectable estradiol: Lowest E1/E2 ratio of ~0.84 5
The biological effects of the elevated estrone and estrone-sulfate levels produced by oral administration remain incompletely understood, but emerging evidence suggests they may be unfavorable 4, 2, 3.
Clinical Recommendations for Hormone Replacement Therapy
For menopausal hormone therapy, transdermal estradiol is preferable to oral formulations for most women, particularly those with cardiovascular or thrombotic risk factors. 4
Specific Indications for Transdermal Over Oral Estradiol:
- Venous thromboembolism (VTE) risk - transdermal therapy at low doses shows lower VTE risk 4
- Hypertension
- Hypertriglyceridemia
- Obesity or metabolic syndrome
- Diabetes
- History of gallbladder disease
The primary advantage of transdermal delivery is avoiding first-pass hepatic metabolism, which eliminates the procoagulant effects and increases in sex hormone-binding globulin (SHBG), thyroid-binding globulin, triglycerides, and inflammatory markers like C-reactive protein seen with oral estrogens 4.
Dosing Strategy:
Use the lowest effective dose with upward titration based on clinical response 4. Starting doses should generally be lower than those used in the Women's Health Initiative trials. For example:
- Standard starting dose: Transdermal estradiol 50 mcg daily
- Younger women with surgical menopause or premature ovarian insufficiency: Higher starting doses (e.g., 100 mcg transdermal) may be appropriate, then taper as tolerated 4
Estradiol levels are not routinely monitored except when symptoms fail to improve with escalating doses, particularly after switching from oral to transdermal administration 4.
Critical Caveat:
Women with an intact uterus require concomitant progestogen to prevent endometrial hyperplasia and cancer, regardless of estrogen formulation or route 4, 1.
Lipid Effects Differ Between Estrone and Estradiol
When comparing oral estrone sulfate versus oral 17β-estradiol at equivalent serum concentrations:
- Estrone sulfate decreases total and LDL cholesterol while increasing HDL cholesterol, without affecting triglycerides 6
- 17β-Estradiol increases total cholesterol, HDL cholesterol, and triglycerides without affecting LDL cholesterol 6
These differential effects are attributed to first-pass hepatic metabolism 6.
Important Clinical Pitfalls:
Do not assume all estrogens are equivalent - estrone and estradiol have distinct biological activities that extend beyond simple potency differences 2, 3
Oral estradiol is largely converted to estrone through hepatic metabolism, creating an unphysiologic hormonal profile 4, 7
High estrone-to-estradiol ratios may be detrimental based on emerging mechanistic data showing pro-inflammatory and EMT-inducing effects 2, 3
No head-to-head RCTs with clinical outcomes directly compare transdermal versus oral estrogen therapy, though mechanistic and surrogate marker data strongly favor transdermal administration for most patients 4